{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:08:16Z","timestamp":1780337296410,"version":"3.54.1"},"reference-count":49,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Programmed death-ligand 1 (PD-L1) expression is commonly used as a predictive biomarker in metastatic non-small cell lung cancer (NSCLC); however, its clinical utility in real-world settings remains uncertain. This study evaluated the association between PD-L1 expression and treatment outcomes in patients receiving immune checkpoint inhibitors (ICIs). Methods: In this retrospective, single-center study, 86 patients with metastatic NSCLC treated with ICIs (pembrolizumab or atezolizumab) between January 2020 and December 2025 were included. PD-L1 expression was assessed using 22C3 or SP263 assays and categorized as &lt;50% and \u226550%. The primary endpoint was time to progression (TTP), while the secondary endpoint was objective response rate (ORR). Survival analyses were performed using Kaplan\u2013Meier estimates, log-rank tests, and Cox proportional hazards models. Results: PD-L1 data were available for 78 of the 86 patients. The median age was 66 years (IQR 61\u201373); 76.7% of patients were male and 65.1% were former smokers. Adenocarcinoma was the predominant histological subtype (47.7%), followed by squamous cell carcinoma (41.9%). The ORR was similar between treatment groups (atezolizumab: 62.5%; pembrolizumab: 64.9%; p = 0.84). No statistically significant difference in TTP was observed between PD-L1 &lt;50% and \u226550% groups. Kaplan\u2013Meier analysis showed no statistically significant difference in TTP between PD-L1 groups (log-rank p = 0.094), although a numerical trend toward shorter TTP was observed in patients with PD-L1 \u226550%. In multivariate Cox regression analysis, PD-L1 \u226550% was not associated with TTP (hazard ratio [HR] 1.53, 95% confidence interval [CI] 0.77\u20133.05; p = 0.20). No other clinical variables, including smoking status and liver metastases, were significantly associated with outcomes. Conclusions: In this limited, retrospective single-center cohort with a heterogeneous treatment mix (chemo-immunotherapy and immunotherapy monotherapy), PD-L1 expression was not significantly associated with treatment response or time to progression. While these results should be interpreted cautiously given the modest sample size and the small number of progression events, they are consistent with broader real-world evidence indicating that PD-L1 expression alone may not reliably stratify clinical benefit in metastatic NSCLC. Larger prospective studies integrating PD-L1 with complementary biomarkers are needed to confirm these observations.<\/jats:p>","DOI":"10.3390\/jcm15114191","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:36:18Z","timestamp":1780076178000},"page":"4191","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1 Expression as a Predictor of Time to Progression in Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Single-Center Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Marija","family":"Simonovska","sequence":"first","affiliation":[{"name":"University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia"},{"name":"Faculty of Medicine, University of Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9705-853X","authenticated-orcid":false,"given":"Jasmina","family":"Djundeva","sequence":"additional","affiliation":[{"name":"University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7172-9589","authenticated-orcid":false,"given":"Bojana Petreska","family":"Kapsarov","sequence":"additional","affiliation":[{"name":"University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julijana","family":"Stefanoska","sequence":"additional","affiliation":[{"name":"University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Vukasinovikj","family":"Stoleska","sequence":"additional","affiliation":[{"name":"University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Eftimov","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Pathology, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of NSCLC","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"KEYNOTE-189. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"KEYNOTE-042. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1\u2013expressing, locally advanced or metastatic non\u2013small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"CheckMate 026 Investigators. First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1200\/JCO.2009.25.5414","article-title":"Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials","volume":"28","author":"Saad","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: Towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC (IMpower110): A phase 3, randomised, open-label trial","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC (IMpower150): A multicentre, open-label, phase 3 trial","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non\u2013small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1634\/theoncologist.2017-0353","article-title":"Characteristics of Real-world Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval","volume":"23","author":"Khozin","year":"2018","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Velcheti, V., Patwardhan, P.D., Liu, F.X., Chen, X., Cao, X., and Burke, T. (2018). Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206370"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2021.04.007","article-title":"Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer","volume":"156","author":"Waterhouse","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non\u2013small cell lung cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"Blueprint PD-L1 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"PD-L1 essays","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_27","first-page":"321","article-title":"Cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Immunity"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"TMB and response","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"Immune infiltration","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.critrevonc.2020.102893","article-title":"The effect of liver metastases on efficacy of immunotherapy plus chemotherapy in advanced lung cancer: A systematic review and meta-analysis","volume":"147","author":"Qin","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/1078-0432.CCR-21-1193","article-title":"The liver-immunity nexus and cancer immunotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bilen, M.A., Shabto, J.M., Martini, D.J., Liu, Y., Lewis, C., Collins, H., Akce, M., Kissick, H.T., Carthon, B.C., and Shaib, W.L. (2019). Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy BMS. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6073-7"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zheng, Y., and Tian, Z. (2019). Liver-Mediated Adaptive Immune Tolerance. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02525"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"Liver immunology","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_39","first-page":"373","article-title":"Association of smoking history with sensitivity to PD-1 blockade in patients with non-small cell lung cancer","volume":"34","author":"Gainor","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"B Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"Biomarker strategies","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"I Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-22-1931","article-title":"Gallium-68-labeled peptide PET quantifies tumor exposure of PD-L1 therapeutics","volume":"29","author":"Mishra","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e007535","DOI":"10.1136\/jitc-2023-007535","article-title":"Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy","volume":"11","author":"Mishra","year":"2023","journal-title":"J. Immunother. Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4191\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:24:38Z","timestamp":1780334678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114191"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114191","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}